Endevica Bio, a US-based company developing first-in-class peptide drug candidates, announced on Friday the spin-off of a newly created company called Abisati, to produce an oral weight loss treatment that has indicated efficacy in animal studies.

The peptide, 710GO, was spun out of the company's platform of experimental drugs to the newly created company, which intends to carry out a phase one trial on the drug from the second half of 2025.

Based in Northbrook, Illinois the new company will concentrate exclusively on bringing the weight-loss drug to market.

Russell Potterfield, CEO and executive chairman of Endevica Bio and of Abisati, said, 'We are so excited about the prospects for a drug that could be life-changing for millions of people suffering from obesity. Our peptide has the potential to help patients lose weight without the side effects such as nausea and vomiting seen with drugs now on the market and without the 'bounce back' weight gain that can happen after patients discontinue medication.'